Enhancing the Role of Lung Cancer Screening CT in Identifying Incidental Findings

Low-dose lung cancer screening (LCS) CT scans are instrumental in revealing a variety of findings beyond just lung nodules, including conditions like coronary artery calcification, emphysema, osteoporosis, thoracic aortic aneurysms, and upper abdominal lesions. The challenge for radiologists lies in determining which of these incidental findings necessitate reporting, follow-up, and intervention.

Dr. Suzanne Byrne, a thoracic radiologist and director of the Lung Cancer Screening Program at Mass General Brigham, points out that while there is a perception that incidental findings lead to unnecessary downstream testing, this notion may not always hold true. "Lung cancer screening CT offers a unique opportunity to identify clinically important findings in a high-risk population," she stated.

Dr. Byrne has co-authored a RadioGraphics article that presents an evidence-based framework aimed at properly identifying, reporting, and managing incidental findings on LCS CT.

The variability in radiology reporting and clinical guidelines complicates consistent implementation of guidance for incidental findings. Dr. Byrne notes that this inconsistency can lead to both unnecessary investigations and the risk of missing significant findings. To overcome these challenges, she advocates for standardized reporting templates, harmonized guidelines, integrated clinical decision support, and effective communication between clinicians and patients.

Approximately one-third of low-dose LCS CTs analyzed in the National Lung Screening Trial (NLST) indicated incidental abnormalities. Among these, emphysema is particularly significant; it is associated with increased mortality rates, even in patients showing normal spirometry. The NLST identified that roughly 31% of participants had emphysema, with a notable 80% previously undiagnosed.

Artificial intelligence (AI)-based tools are suggested for rapid, standardized reporting of findings. By effectively integrating assessments and recommendations for smoking cessation, pulmonary function testing, and referrals, radiologists can ensure prompt management of conditions like emphysema.

Additionally, interstitial lung abnormalities (ILAs) are present in about 4% to 17% of LCS CT examinations. Despite their potential for progression, these abnormalities are often underreported, leading to diagnostic delays. The American Thoracic Society and Fleischner Society advocate for thorough documentation of ILAs in reports, alongside risk assessments and management strategies.

Dr. Byrne also highlights the common occurrence of coronary artery calcium (CAC) in lung cancer screening cohorts. She encourages routine documentation of CAC findings in the report impressions to promote follow-up without incurring additional costs or radiation exposure.

Moreover, incidental findings related to osteoporosis and abdominal lesions can lead to significant health interventions. The capability of LCS CT to assess vertebral bone density offers a chance to diagnose osteoporosis, which often goes undetected until fractures occur.

Ultimately, Dr. Byrne emphasizes that the focus should not be on pursuing every incidental finding but rather on implementing structured reporting. This approach aids in distinguishing actionable findings from less critical ones, thereby minimizing unnecessary investigations and patient anxiety while ensuring important findings are prioritized for follow-up. By harnessing advanced technologies like AI, the potential exists to broaden the scope of lung cancer screening, contributing to enhanced health outcomes across a spectrum of chronic diseases.